Current status and progress of recurrence of retinopathy in prematurity after intravitreal injection with anti-vascular endothelial growth factor drugs

Q4 Medicine

中华眼底病杂志 Pub Date : 2019-11-25 DOI:10.3760/CMA.J.ISSN.1005-1015.2019.06.024

Qian Yang

引用次数: 0

Abstract

Intravitreal injection of anti-VEGF drugs for the treatment of retinopathy of prematurity(ROP) is a hot topic of research, and it can be used to treat the ROP (Ⅰzone). The current anti-VEGF drugs include bevacizumab, ranibizumab, aflibercept and conbercept, etc. However, in recent years, several studies have confirmed that anti-VEGF drugs have an increased recurrence rate and a longer recurrence time than conventional laser photocoagulation therapy. The follow-up period should be extended and repeated injections may be required. Due to the lack of large-scale prospective clinical studies, the recurrence rate, time window of recurrence, risk factors and treatment methods of various anti-VEGF drugs for ROP are still unclear. Anti-VEGF drugs in the treatment of ROP needs to accumulate more evidence-based medical evidence. Key words: Retinopathy of prematurity/drug therapy; Angiogenesis inhibitors/therapeutic use; Recurrence; Review

查看原文本刊更多论文

早产儿视网膜病变玻璃体内注射抗血管内皮生长因子药物后复发的现状与进展

玻璃体内注射抗VEGF药物治疗早产儿视网膜病变（ROP）是目前研究的热点，可用于治疗ROP（Ⅰ区）。目前的抗VEGF药物包括贝伐单抗、雷珠单抗、阿法西普和康柏西普等。然而，近年来的几项研究证实，抗VEGF药物比传统的激光光凝治疗具有更高的复发率和更长的复发时间。随访期应延长，可能需要重复注射。由于缺乏大规模前瞻性临床研究，各种抗VEGF药物治疗ROP的复发率、复发时间窗、危险因素和治疗方法尚不清楚。抗VEGF药物治疗ROP需要积累更多循证医学证据。关键词：早产儿视网膜病变/药物治疗；血管生成抑制剂/治疗用途；复发；审查

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华眼底病杂志 Medicine-Ophthalmology

CiteScore

0.40

自引率

0.00%

发文量

5383

期刊介绍： Chinese Journal of Ocular Fundus Diseases is the only scientific journal in my country that focuses on reporting fundus diseases. Its purpose is to combine clinical and basic research, and to give equal importance to improvement and popularization. It comprehensively reflects the leading clinical and basic research results of fundus disease disciplines in my country; cultivates professional talents in fundus disease, promotes the development of fundus disease disciplines in my country; and promotes academic exchanges on fundus disease at home and abroad. The coverage includes clinical and basic research results of posterior segment diseases such as retina, uveal tract, vitreous body, visual pathway, and internal eye diseases related to systemic diseases. The readers are medical workers and researchers related to clinical and basic research of fundus diseases. According to the journal retrieval report of the Chinese Institute of Scientific and Technological Information, the comprehensive ranking impact factor and total citation frequency of the Chinese Journal of Ocular Fundus Diseases have been among the best in the disciplines of ophthalmology, otolaryngology, and ophthalmology in my country for many years. The papers published have been included in many important databases at home and abroad, such as Scopus, Peking University Core, and China Science Citation Database (CSCD).